Search

Displaying results 2701 - 2710 of 10000 in total
  1. Drug

    Metyrosine

    go.drugbank.com/drugs/DB00765
    ApprovedInvestigational

    An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. … It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)

  2. Drug

    Flucloxacillin

    go.drugbank.com/drugs/DB00301
    ApprovedInvestigationalWithdrawn

    Antibiotic analog of [cloxacillin].

    Categories: combinations of penicillinsProducts: Floxapen 500 mg Kapseln, Floxapen 1 g Trockenstechampullen
  3. Drug

    Choline salicylate

    go.drugbank.com/drugs/DB14006
    ApprovedNutraceutical

    Choline Salicylate is the choline salt of salicylic acid, used as an analgesic, antipyretic and antirheumatic. It relieves mild to moderate pain and reduce fever and inflammation or swelling. … The UK government has regulated its use, due to toxicity in those under 16 years of age.

    Products: DENCOL JEL SPREY, 20 G, Colident %8.71 jel sprey, 20 G
  4. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. … It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020.

    Products: ZEPOSİA 0,92 MG SERT KAPSÜL, 28 ADET
  5. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    It was FDA approved in 2015 for the treatment of basal cell carcinoma.

  6. Drug

    Phenacemide

    go.drugbank.com/drugs/DB01121
    Approved

    Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.

  7. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … [L64112] The European Commission granted marketing authorization on August 24, 2026 for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged 5 years and older

  8. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration … [L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim

    Synonyms: Rh g-csf fc fusion protein f-627, Recombinant dimeric g-csf fusion protein f627
  9. Drug

    Guaiacol

    go.drugbank.com/drugs/DB11359
    Approved

    Guaiacol is a phenolic natural product first isolated from Guaiac resin and the oxidation of lignin. Guaiacol is also present in wood smoke, as a product of pyrolysis of lignin. … Guaiacol has been found in the urine of patients with neuroblastoma and pheochromocytoma.

    Synonyms: o-guaiacol, o-Methoxyphenol
  10. Drug

    Selumetinib

    go.drugbank.com/drugs/DB11689
    ApprovedInvestigational

    tools that can target the problematic overactivity of this pathway. … [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved.

    Products: Koselugo Hard Capsules 10 mg, Koselugo Hard Capsules 25 mg